首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1481812

全球生物工程蛋白藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Bioengineered Protein Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月07日 | 出版商:

Value Market Research | 英文 234 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球生物工程蛋白藥物市場需求預計將從 2023 年的 3,467.6 億美元達到近 6,455.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.15%。

生物工程蛋白質藥物是利用生物技術生產模仿體內自然存在的蛋白質的藥品。這些藥物針對疾病過程中涉及的特定生物途徑或分子，為自體免疫疾病、癌症和遺傳性疾病等各種醫療狀況提供標靶治療。這些藥物是利用重組 DNA 技術生產的，其中編碼所需蛋白質的基因被插入宿主細胞中，如酵母、細菌或哺乳動物細胞，這些細胞充當微型蛋白質工廠。與傳統藥物相比，這些藥物提供高效、更有針對性且副作用更少的療法，徹底改變了醫學治療。

市場動態

癌症、自體免疫疾病和代謝疾病等慢性病的盛行率不斷上升，推動了對標靶生物療法的需求，這些療法比傳統藥物可提高療效並減少副作用。生物工程蛋白質藥物，包括單株抗體、細胞激素和生長因子，可以精確靶向和調節疾病途徑，從而改善患者的治療結果和生活品質。此外，生物技術和基因工程技術的進步使得能夠開發出具有增強效力、特異性和穩定性的新型蛋白質療法，從而擴大了患者和醫療保健提供者可用的治療選擇。此外，生物製藥公司和學術機構對研發的投資不斷增加，正在推動生物工程蛋白質藥物發現和開發的創新，從而發現新的藥物標靶和治療方式。此外，擴大採用個人化醫療方法和生物標記驅動的治療策略，推動了對根據個別患者特徵和疾病概況客製化的生物工程蛋白藥物的需求，從而改善治療結果並降低醫療成本。包括 FDA 和 CMS 在內的監管機構和付款人越來越接受生物工程蛋白藥物，這促進了這些創新療法的市場准入和報銷，進一步推動了市場成長和採用。然而，生物製藥和替代治療方式的進步可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球生物工程蛋白藥物市場的各個細分市場進行了包容性評估。生物工程蛋白藥物產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

生物工程蛋白藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

依藥物類型

單株抗體（Humira、Rituxan、Avastin、Herceptin、Remicade、Lucentis、Enbrel、Synazis 等）
治療性蛋白質（荷爾蒙、細胞激素（Neupogen、Neulasta、干擾素α、紅血球生成素α、白血球介素等）血液因子、酵素療法（全身性酵素療法、消化酵素療法）、血栓溶解劑（tPA鏈激酶、尿激酶））
疫苗

按病情

癌症
糖尿病
自體免疫疾病
傳染病
造血作用
CVD
神經退化性疾病
其他

按最終用戶

製藥和生物技術公司
合約研究組織
研究機構

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲生物工程蛋白藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。生物工程蛋白藥物市場的主要參與者包括雅培、安進公司、拜耳公司、Biocon、雷迪博士實驗室、禮來公司、F.霍夫曼-拉羅氏有限公司、費森尤斯卡比公司、葛蘭素史克、楊森全球服務公司、默克公司. Inc.、諾華公司、Panacea Biotec、ProBioGen AG、Reliance Life Science、賽諾菲。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

按藥物類型概述
歷史和預測數據
依藥物類型分析
單株抗體（Humira、Rituxan、Avastin、Herceptin、Remicade、Lucentis、Enbrel、Synazis 等）
治療性蛋白質（荷爾蒙、細胞激素（Neupogen、Neulasta、干擾素α、紅血球生成素α、白血球介素等）血液因子、酵素療法（全身性酵素療法、消化酵素療法）、血栓溶解劑（tPA鏈激酶、尿激酶））
疫苗

第 6 章：全球生物工程蛋白藥物市場分析：依疾病狀況

按疾病狀況概述
歷史和預測數據
按病情分析
癌症
糖尿病
自體免疫疾病
傳染病
造血作用
CVD
神經退化性疾病
其他

第 7 章：全球生物工程蛋白藥物市場分析：依最終使用者分類

最終用戶概述
歷史和預測數據
最終用戶分析
製藥和生物技術公司
合約研究組織
研究機構

第 8 章：全球生物工程蛋白藥物市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：生物工程蛋白藥物公司的競爭格局

生物工程蛋白質藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott

公司簡介
公司收入
產品
最近的發展

Amgen Inc.

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Biocon

公司簡介
公司收入
產品
最近的發展

Dr. Reddy'S Laboratories

公司簡介
公司收入
產品
最近的發展

Lilly

公司簡介
公司收入
產品
最近的發展

F. Hoffmann - La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Fresenius Kabi AG

公司簡介
公司收入
產品
最近的發展

公司簡介
公司收入
產品
最近的發展

Janssen Global Services

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Panacea Biotec

公司簡介
公司收入
產品
最近的發展

ProBioGen AG

公司簡介
公司收入
產品
最近的發展

Reliance Life Science

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114477

The global demand for Bioengineered Protein Drugs Market is presumed to reach the market size of nearly USD 645.59 Billion by 2032 from USD 346.76 Billion in 2023 with a CAGR of 7.15% under the study period 2024-2032.

Bioengineered protein drugs are pharmaceutical products created using biotechnology techniques to produce proteins that mimic those naturally occurring in the body. These drugs target specific biological pathways or molecules involved in disease processes, offering targeted therapies for various medical conditions such as autoimmune disorders, cancer, and genetic diseases. These drugs are produced using recombinant DNA technology, where genes encoding the desired protein are inserted into host cells such as yeast, bacteria, or mammalian cells, which act as miniature protein factories. These drugs have revolutionized medical treatment by providing highly effective and often more targeted therapies with fewer side effects compared to traditional drugs.

MARKET DYNAMICS

The proliferating prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic diseases is driving the demand for targeted and biologically-based therapies that offer enhanced efficacy & reduced side effects than traditional pharmaceuticals. Bioengineered protein drugs, including monoclonal antibodies, cytokines, and growth factors, provide precise targeting and modulation of disease pathways, leading to better patient outcomes and quality of life. Additionally, advancements in biotechnology and genetic engineering techniques allow the development of novel protein therapeutics with enhanced potency, specificity, and stability, expanding the therapeutic options available to patients and healthcare providers. Moreover, the growing investment in research and development by biopharmaceutical companies and academic institutions is driving innovation in bioengineered protein drug discovery and development, leading to the discovery of novel drug targets and therapeutic modalities. Furthermore, the increasing adoption of personalized medicine approaches and biomarker-driven treatment strategies drives demand for bioengineered protein drugs tailored to individual patient characteristics and disease profiles, improving treatment outcomes and reducing healthcare costs. The growing acceptance of bioengineered protein drugs by regulatory agencies and payers, including the FDA and CMS, facilitates market access and reimbursement for these innovative therapies, further driving market growth and adoption. However, advancements in biopharmaceuticals and alternative treatment modalities may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bioengineered Protein Drugs. The growth and trends of Bioengineered Protein Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bioengineered Protein Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase))
Vaccines

By Disease Condition

Cancer
Diabetes
Autoimmune Disorder
Infectious Disease
Hematopoiesis
CVD
Neurodegenerative
Others

By End-user

Pharma and Biotech Companies
CROs
Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bioengineered Protein Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bioengineered Protein Drugs market include Abbott, Amgen Inc., Bayer AG, Biocon, Dr. Reddy'S Laboratories, Lilly, F. Hoffmann - La Roche Ltd., Fresenius Kabi AG, GSK, Janssen Global Services, Merck & Co. Inc., Novartis AG, Panacea Biotec, ProBioGen AG, Reliance Life Science, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BIOENGINEERED PROTEIN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Disease Condition
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Historic and Forecast Sales By Regions
5.5. Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Historic and Forecast Sales By Regions
5.6. Vaccines Historic and Forecast Sales By Regions

6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DISEASE CONDITION

6.1. Overview By Disease Condition
6.2. Historical and Forecast Data
6.3. Analysis By Disease Condition
6.4. Cancer Historic and Forecast Sales By Regions
6.5. Diabetes Historic and Forecast Sales By Regions
6.6. Autoimmune Disorder Historic and Forecast Sales By Regions
6.7. Infectious Disease Historic and Forecast Sales By Regions
6.8. Hematopoiesis Historic and Forecast Sales By Regions
6.9. CVD Historic and Forecast Sales By Regions
6.10. Neurodegenerative Historic and Forecast Sales By Regions
6.11. Others Historic and Forecast Sales By Regions

7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Pharma and Biotech Companies Historic and Forecast Sales By Regions
7.5. CROs Historic and Forecast Sales By Regions
7.6. Research Institutes Historic and Forecast Sales By Regions

8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BIOENGINEERED PROTEIN DRUGS COMPANIES

9.1. Bioengineered Protein Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF BIOENGINEERED PROTEIN DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Amgen Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Bayer AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Biocon
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Dr. Reddy'S Laboratories
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Lilly
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. F. Hoffmann - La Roche Ltd.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Fresenius Kabi AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. GSK
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Janssen Global Services
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Merck & Co. Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Novartis AG
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Panacea Biotec
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. ProBioGen AG
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Reliance Life Science
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Sanofi
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Drug Type (USD MN)
Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Market Sales By Geography (USD MN)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Market Sales By Geography (USD MN)
Vaccines Market Sales By Geography (USD MN)
Analysis By Disease Condition (USD MN)
Cancer Market Sales By Geography (USD MN)
Diabetes Market Sales By Geography (USD MN)
Autoimmune Disorder Market Sales By Geography (USD MN)
Infectious Disease Market Sales By Geography (USD MN)
Hematopoiesis Market Sales By Geography (USD MN)
CVD Market Sales By Geography (USD MN)
Neurodegenerative Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By End-user (USD MN)
Pharma and Biotech Companies Market Sales By Geography (USD MN)
CROs Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Global Bioengineered Protein Drugs Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Bioengineered Protein Drugs Report
Market Research Process
Market Research Methodology
Global Bioengineered Protein Drugs Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Drug Type
Market Attractiveness Analysis By Disease Condition
Market Attractiveness Analysis By End-user
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Drug Type (USD MN)
Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Market Sales By Geography (USD MN)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Market Sales By Geography (USD MN)
Vaccines Market Sales By Geography (USD MN)
Global Market Analysis By Disease Condition (USD MN)
Cancer Market Sales By Geography (USD MN)
Diabetes Market Sales By Geography (USD MN)
Autoimmune Disorder Market Sales By Geography (USD MN)
Infectious Disease Market Sales By Geography (USD MN)
Hematopoiesis Market Sales By Geography (USD MN)
CVD Market Sales By Geography (USD MN)
Neurodegenerative Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By End-user (USD MN)
Pharma and Biotech Companies Market Sales By Geography (USD MN)
CROs Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis